European Society for Medical Oncology, 2024 - Care Complexity
Assessing Care Complexity in Oncology Medical Remote Monitoring: A Cohort Study of 2,912 Patients.
Dec 4, 2025
2 minutes
Authors
Capucine Baldini 1, Thomas Grellety 2, Rabia Boulahssass 3, Pierre Soubeyran 4, Etienne Brain 5, Loïc Mourey 6, Claire Dumas-Bonnetain 7, Florence Canouï-Poitrine 8, Romain Rivoirard 9, Amine Diab 10, Élodie Nouhaud 10, Maximilien Autheman 10, Juliette Fanton d’Andon 10, Jules Ancillon 10, Charles Ferté 10, Christophe Massard 1, Florian Scotté 1, Nicolas Bertrand 11.
Affiliation
1. Gustave Roussy, Villejuif, France ; 2. Centre Hospitalier de la Côte Basque, Bayonne, France ; 3. Centre Hospitalier Universitaire de Nice, France ; 4. Institut Bergonié, Bordeaux, France ; 5. Institut Curie, Paris, France ; 6. Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France ; 7. Unicancer, Paris, France ; 8. Assistance Publique des Hôpitaux de Paris, Hôpital Henri Mondor, Créteil, France ; 9. Hôpital Privé de la Loire, Saint-Etienne, France ; 10. Resilience, Paris, France ; 11. Centre Eugène Marquis, Rennes, France.
Introduction
Medical remote monitoring based on ePROs (electronic Patient-Reported Outcomes) has demonstrated clinical and organizational benefits through Phase III randomized controlled clinical trials [1-4]. These benefits include:
- Symptom control,
- Quality of life,
- Increased relative dose intensity,
- Reduction in the number of hospitalizations,
- Prolongation of overall survival.
Consequently, in 2022, ESMO published its recommendations regarding medical remote monitoring for routine clinical practice during anti-cancer treatments[5].
However, factors related to care complexity regarding oncology remote monitoring remain largely unknown. Identifying these factors would enable the provision of personalized care.
This study aims to define the care complexity factors regarding oncology medical remote monitoring, in order to determine a Care Complexity Score usable in routine practice.
Poster presented at the 2024 ESMO (European Society of Medical Oncology) Congress.
Sources
1. Mir O, Ferrua M, Fourcade A, et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med.2022;28(6):1224-1231.
2. Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA. 2022;327(24):2413-2422.
3. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2019 Feb20;37(6):528.
4. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA.2017;318(2):197-198.
5. Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(9):878-892. doi:10.1016/j.annonc.2022.04.007.
